Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Retained Earnings (2020 - 2025)

SAB Biotherapeutics' Retained Earnings history spans 6 years, with the latest figure at $186510.0 for Q4 2025.

  • For Q4 2025, Retained Earnings rose 100.15% year-over-year to $186510.0; the TTM value through Dec 2025 reached $186510.0, up 100.15%, while the annual FY2025 figure was $186510.0, 100.15% up from the prior year.
  • Retained Earnings reached $186510.0 in Q4 2025 per SABSW's latest filing, up from -$94.0 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $186510.0 in Q4 2025 to a low of -$129.4 million in Q1 2025.
  • Average Retained Earnings over 5 years is -$56.8 million, with a median of -$51.5 million recorded in 2022.
  • Peak YoY movement for Retained Earnings: tumbled 330.35% in 2022, then skyrocketed 100.15% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$29.1 million in 2021, then tumbled by 64.34% to -$47.9 million in 2022, then tumbled by 88.14% to -$90.1 million in 2023, then tumbled by 37.87% to -$124.2 million in 2024, then skyrocketed by 100.15% to $186510.0 in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Retained Earnings are $186510.0 (Q4 2025), -$94.0 million (Q3 2025), and -$15805.0 (Q2 2025).